Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214746 | 1.00 | NT5E (0.43) | NT5ETDP1P2RY2P2RY12P2RY6 | |
| SCHEMBL13396754 | 1.00 | NT5E (0.43) | NT5ETDP1P2RY2P2RY12P2RY6 | |
| SCHEMBL24371466 | 0.93 | NT5E (0.36) | NT5ETDP1P2RY2P2RY6 | |
| SCHEMBL21418831 | 0.93 | NT5E (0.36) | NT5ETDP1P2RY2P2RY6 | |
| SCHEMBL21418828 | 0.93 | NT5E (0.36) | NT5ETDP1P2RY2P2RY6 | |
| SCHEMBL24244849 | 0.88 | TK1 (0.38) | NT5E | |
| SCHEMBL24244831 | 0.88 | TK1 (0.38) | NT5E | |
| SCHEMBL24499108 | 0.88 | TK1 (0.38) | NT5E | |
| SCHEMBL22609164 | 0.87 | TDP1 (0.38) | NT5ETDP1P2RY2P2RY12P2RY6 | |
| SCHEMBL23054812 | 0.87 | TDP1 (0.38) | NT5ETDP1P2RY2P2RY12P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177201-B1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-1177202-B1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-1177202-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | NT5E 32/4885TDP1 315/4885P2RY2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.